Michael YuPartner at Cooley LLP
Mr. Michael Yu’s practice focuses on initial public offerings and other equity capital markets transactions on the Hong Kong Stock Exchange, pre-IPO investments, public takeovers and listing rules and securities regulations compliance.
Michael has actively participated in the strategic initiative by the Hong Kong Stock Exchange to attract new-economy companies to list in Hong Kong. In particular, he advised Ascletis Pharma on its $400 million Hong Kong IPO in 2018, the first pre-revenue biotech IPO on the HKEX under its new listing regime for companies from emerging and innovative sectors. He has also advised a number of new-economy companies, including companies in biotech and internet sectors, on their Hong Kong IPOs.
Michael received his LLM from New York University School of Law and Peking University Law School. He was recognized in IFLR1000 2019 and 2020 as a Notable Practitioner for equity capital markets work.